 Metformin
"Metformin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
| Descriptor ID |
D008687
|
| MeSH Number(s) |
D02.078.370.141.450
|
| Concept/Terms |
Metformin- Metformin
- Dimethylbiguanidine
- Dimethylguanylguanidine
|
Below are MeSH descriptors whose meaning is more general than "Metformin".
Below are MeSH descriptors whose meaning is more specific than "Metformin".
This graph shows the total number of publications written about "Metformin" by people in this website by year, and whether "Metformin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 3 | 5 | | 2006 | 1 | 2 | 3 | | 2007 | 3 | 4 | 7 | | 2008 | 3 | 3 | 6 | | 2009 | 6 | 3 | 9 | | 2010 | 1 | 3 | 4 | | 2011 | 3 | 1 | 4 | | 2012 | 5 | 5 | 10 | | 2013 | 4 | 2 | 6 | | 2014 | 5 | 4 | 9 | | 2015 | 9 | 3 | 12 | | 2016 | 3 | 3 | 6 | | 2017 | 10 | 6 | 16 | | 2018 | 11 | 4 | 15 | | 2019 | 6 | 6 | 12 | | 2020 | 10 | 2 | 12 | | 2021 | 17 | 5 | 22 | | 2022 | 9 | 2 | 11 | | 2023 | 13 | 1 | 14 | | 2024 | 13 | 1 | 14 | | 2025 | 3 | 3 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Metformin" by people in Profiles.
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 Jul; 27(7):3943-3956.
-
Knowler WC, Doherty L, Edelstein SL, Bennett PH, Dabelea D, Hoskin M, Kahn SE, Kalyani RR, Kim C, Pi-Sunyer FX, Raghavan S, Shah VO, Temprosa M, Venditti EM, Nathan DM. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025 Jun; 13(6):469-481.
-
Hosseini M, Voisin V, Chegini A, Varesi A, Cathelin S, Ayyathan DM, Liu ACH, Yang Y, Wang V, Maher A, Grignano E, Reisz JA, D'Alessandro A, Young K, Wu Y, Fiumara M, Ferrari S, Naldini L, Gaiti F, Pai S, Egan G, Schimmer AD, Bader GD, Dick JE, Xie SZ, Trowbridge JJ, Chan SM. Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs. Nature. 2025 Jun; 642(8067):421-430.
-
Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, Bergenstal RM, Brown N, Carlson AL, DeFronzo RA, Gramzinski MR, Harindhanavudhi T, Kozedub A, Sivitz WI, Steffes MW, Balasubramanyam A, Rasouli N. Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Witham MD, McDonald C, Wilson N, Rennie KJ, Bardgett M, Bradley P, Clegg AP, Connolly S, Hancock H, Hiu S, Nicholson K, Robertson L, Simms L, Steel AJ, Steves CJ, Storey B, Wason J, von Zglinicki T, Sayer AA. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England?(MET-PREVENT): a double-blind, randomised, placebo-controlled trial. Lancet Healthy Longev. 2025 Mar; 6(3):100695.
-
Shen J, Sarwal A, Singh R, Hartsell SE, Wei G, Nevers M, Christensen JC, Takyi A, Katkam N, Derington CG, Deshmukh VG, Boucher RE, Drakos SG, Greene T, Beddhu S. Comparative effectiveness of insulin glargine, glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in veterans with type 2 diabetes. Diabetes Obes Metab. 2025 Apr; 27(4):2120-2130.
-
Nadeau KJ, Arslanian SA, Bacha F, Caprio S, Chao LC, Farrell R, Hughan KS, Rayas M, Tung M, Cross K, El Ghormli L. Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia. 2025 Mar; 68(3):676-687.
-
Dumont LJ, Kelly K, Nemkov T, Leite C, Gresens CJ, Stanley C, D'Alessandro A, Vassallo RR. Platelet storage failure-Metformin as causative agent. Transfusion. 2024 Dec; 64(12):2405-2409.
-
Johnson SG, Abedian S, St?rmer T, Huling JD, Lewis V C, Buse JB, Brosnahan SB, Mudumbi PC, Erlandson KM, McComsey GA, Arnold J, Wiggen TD, Wong R, Murphy S, Rosen C, Kaushal R, Weiner MG, Bramante C. Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program. Diabetes Care. 2024 Nov 01; 47(11):1930-1940.
-
Xiao JF, Luo W, Mani A, Barba H, Solanki A, Droho S, Lavine JA, Skondra D. Intravitreal Metformin Protects Against Choroidal Neovascularization and Light-Induced Retinal Degeneration. Int J Mol Sci. 2024 Oct 22; 25(21).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|